Compound: Rubitecan
SMILES: O=[N+]([O-])c1c2c(nc3-c4cc5[C@](O)(C(=O)OCc5c(n4Cc3c2)=O)CC)ccc1
InChIKey: VHXNKPBCCMUMSW-FQEVSTJZSA-N
Synonyms: Rubitecan, 9-Nitrocamptothecin, 91421-42-0, Orathecin, 9-nitro-20(S)-camptothecin, Camptogen, RFS 2000, RFS-2000, Nitrocamptothecin, rubitecanum, RFS2000, 9-nitro-(20S)-camptothecin, H19C446XXB, 9-nitro-20-(S)-camptothecin, DTXSID7046752, CHEBI:90225, DTXCID5026752, 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (4S)-, (19S)-19-ethyl-19-hydroxy-8-nitro-17-oxa-3,13-diazapentacyclo(11.8.0.0^(2,11).0^(4,9).0^(15,20))henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione, (19S)-19-ethyl-19-hydroxy-8-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione, RefChem:883953, 9-nitrocamptothecin, (S)-, NSC603070, 9-NC, (S)-4-Ethyl-4-hydroxy-10-nitro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, MFCD06656294, RFS 2000;9-Nitrocamptothecin, 9NC, NCGC00167969-01, C20H15N3O6, (19S)-19-ethyl-19-hydroxy-8-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione, (4s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione, (s)-4-ethyl-4-hydroxy-10-nitro-1h-pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4h,12h)-dione, Rubitecan [USAN], Rubitecan [USAN:INN], UNII-H19C446XXB, 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-9-nitro-, 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-9-nitro-, 9-nitro camptothecin, RUBITECAN [INN], RUBITECAN [MI], Rubitecan (USAN/INN), Camptothecin Impurity 13, RUBITECAN [MART.], RUBITECAN [WHO-DD], SCHEMBL8640, ethyl-hydroxy-nitro-[?]dione, CHEMBL77305, orb1301430, SCHEMBL29379605, SCHEMBL29383355, WLZ3809, VHXNKPBCCMUMSW-FQEVSTJZSA-N, EX-A4326, Tox21_112597, BDBM50248354, s2288, AKOS015895332, AKOS025149224, DB06159, EBC-615615, FR27767, ST-2617, NCGC00167969-02, NCGC00167969-03, AC-13389, AC-25083, AC-33157, AS-14856, BP-41442, HY-13744, SY078302, CAS-91421-42-0, CS-0007769, N0822, D04031, Q510113, BRD-K79821389-001-01-9, BRD-K79821389-001-03-5, 9-NC, 9-Nitro-camptothecin, Partaject Orathecin, Partaject rubitecan, RFS 2000, (4S)-4-Ethyl-4-hydroxy-10-nitro-1H-pyrano[3',4':6,7]indolizinol[1,2-b]quinoline-3,14(4H,-12H)-dione, (S)-4-ethyl-4-hydroxy-10-nitro-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione, (S)-4-Ethyl-4-hydroxy-10-nitro-1H-pyrano[3\',4\':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
Theoretical properties:
molecular_formula: C20H15N3O6
molecular_weight: 393.3 g/mol
exact_mass: 393.09608521 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 7
rotatable_bond_count: 1
heavy_atom_count: 29
topological_polar_surface_area: 126 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Rubitecan is a pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin. It has a role as an antineoplastic agent, a prodrug and an EC 5.99.1.2 (DNA topoisomerase) inhibitor. It is a delta-lactone, a tertiary alcohol, a C-nitro compound, a pyranoindolizinoquinoline and a semisynthetic derivative.
chebi: A pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin.
chembl: RUBITECAN is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Rubitecan (INN, trade name Orathecin) is an oral topoisomerase inhibitor, developed by SuperGen (now Astex Pharmaceuticals, a member of the Otsuka Group).